Suven Life gets product patents from Europe, Eurasia

Suven Life Sciences on Wednesday said it has received one product patent from Europe, and two patents from Eurasia, related to new entities for the treatment of neuro-degenerative diseases. The patents are from the class of selective 5-HT4 compounds, Alpha4Beta2 and H3 Inverse agonist compounds, and are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neuro-degenerative disorders, such as Alzheimer’s, attention deficient hyperactivity disorder, Huntington’s disease, major depressive disorder, Parkinson’s and schizophrenia. With the new patents, the company has a total of 21 granted patents from Europe and 19 from Eurasia. Shares of Suven Life Sciences closed at ₹207, up 1.4 per cent on the NSE.